6th Asian and Oceanian Parkinson\'s Disease and Movement Disorders Congress

April 12-14, 2019 • Hangzhou

Program-At-A-Glance
Dear Colleagues,

The International Parkinson and Movement Disorder Society (MDS) and the MDS Asian and Oceanic Section (MDS-AOS) warmly invite you to attend 6th Asian and Oceanian Parkinson’s Disease and Movement Disorders Congress (AOPMC), April 12-14, 2019 in Hangzhou.

The AOPMC occurs every two years as a forum to further develop the field of Movement Disorders in the region. Please join us to facilitate communication between clinicians and researchers in the region, disseminate updated knowledge about movement disorders, improve quality of life and independence of movement disorders patients and caregivers, promote research and facilitate research collaborations in movement disorders and expose clinicians, researchers and healthcare professionals in the region to movement disorders initiatives.

We look forward to welcoming you to Hangzhou in April 2019.

Baorong Zhang  
Chair, 6th AOPMC Scientific Program Committee and  
Chair, 6th AOPMC Local Organizing Committee

Beomseok Jeon  
Chair, 6th AOPMC Oversight Committee and  
Chair, MDS-AOS, 2017-2019
# AOPMC Schedule-At-A-Glance

<table>
<thead>
<tr>
<th>Time</th>
<th>Friday, April 12</th>
<th>Saturday, April 13</th>
<th>Sunday, April 14</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td></td>
<td>Plenary Session</td>
<td></td>
</tr>
<tr>
<td>8:30</td>
<td></td>
<td>8:00-9:30</td>
<td></td>
</tr>
<tr>
<td>9:00</td>
<td></td>
<td>Te/Coffee Break</td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td></td>
<td>9:30-10:00</td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td>Plenary Session</td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td>10:00-11:30</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>Sponsored Lunch Symposium</td>
<td>12:00-13:00</td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td>Break</td>
<td>13:00-13:15</td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td>Corporate Symposium</td>
<td>13:15-14:15</td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td>Corporate Symposium</td>
<td>14:30 - 15:30</td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td>Parallel Sessions</td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td>Tea/Coffee Break</td>
<td>15:30-16:00</td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>Corporate Symposium</td>
<td>16:00-17:00</td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td>Tea/Coffee Break</td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td>Break</td>
<td>17:00-17:15</td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td>Corporate Symposium</td>
<td>17:15-18:15</td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td>Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td>Welcome Ceremony</td>
<td>18:30-19:30</td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td>Opening Reception</td>
<td>19:30-20:00</td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td></td>
<td>Video Tournament</td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
<td>18:30-20:30</td>
<td></td>
</tr>
</tbody>
</table>
Saturday, April 13, 2019

2101 Plenary Session
Specific Movement Disorders in the Asian-Oceania Region: Historical and Recent Developments
8:00 - 9:30
Chairs: Haibo Chen, Beijing
Beomseok Jeon, Seoul
8:00 X-linked Dystonia Parkinsonism: A Filipino Disease, A Global Effort
Roland Dominick Jamora, Manila
8:30 Amyotrophic Lateral Sclerosis / Parkinsonism Dementia Complex in the Kii Peninsula
Yasumasa Kokubo, Tsu City
9:00 Paroxysmal Dyskinesia and Genetics with Focus on PRRT2
Zhi-Ying Wu, Hangzhou

At the conclusion of this session, participants should be better able to:
1. Recognize the new developments in the diagnosis and management of X-linked dystonia parkinsonism
2. Recognize the recent developments in the field of ALS-PDC in the Kii Peninsula
3. Discuss the development in the genetics of paroxysmal dyskinesias with special focus on PRRT2

2102 Plenary Session
Genotype-Phenotype Correlation in Ataxia: An Asian Perspective
10:00 - 11:30
Chairs: Chon-Haw Tsai, Taichung
Hirosiwa Watanabe, Nagoya
10:00 The Pathogenesis of Hereditary Ataxia and the Treatment Strategy
Kinya Ishikawa, Tokyo
10:30 Genotype-Phenotype Correlation in Ataxia
Han-Joon Kim, Seoul
11:00 Treatable Ataxia, Not-to-Miss
Yih-Ru Wu, Taipei

At the conclusion of this session, participants should be better able to:
1. Explain the pathogenesis of hereditary ataxia and how to treat
2. Describe the genotype-phenotype correlation
3. Identify the treatable ataxia

2103 Parallel Session
Preclinical and Prodromal Parkinson's Disease: Past, Present and Future
14:30 - 16:00
Chairs: Louis Tan, Singapore
Zhenfu Wang, Beijing
14:30 Pathophysiology of Parkinson's Disease
Carolyn Sue, Sydney
15:00 Clinical Biomarkers of Parkinson's Disease
Jing Zhang, Seattle
15:30 Is Diagnosis of Prodromal Parkinson's Disease Feasible?
Anthony Lang, Toronto

At the conclusion of this session, participants should be better able to:
1. Describe the recent progress in the understanding of pathogenesis of Parkinson's disease
2. Discuss the range of clinical markers and their application in identifying Parkinson's disease including prodromal stage
3. Integrate our understanding of the progression of Parkinson's disease from the prodromal stage

2104 Parallel Session
Unfamiliar Symptoms in Familiar Movement Disorders
14:30 - 16:00
Chairs: Shengdi Chen, Shanghai
Pramod Pal, Bengaluru
14:30 Under-Recognized Motor and Non-Motor Symptoms in Parkinson's Disease and Parkinson Plus Syndrome
Piu Chan, Beijing
15:00 Extra-Cerebellar Signs and Symptoms in Spinocerebellar Ataxias
Jin Whan Cho, Seoul
15:30 Atypical Presentation of Genetic Dystonia
Victor Fung, Sydney

At the conclusion of this session, participants should be better able to:
1. Identify the under-recognized motor and non-motor symptoms in Parkinson's disease and Parkinson plus syndrome
2. Describe extra-cerebellar signs and symptoms in spinocerebellar ataxias
3. Describe atypical presentation of well-known genetic dystonia

2105 Parallel Session
Focusing on New Targets for Therapy in Movement Disorders
14:30 - 16:00
Chairs: Simon Lewis, Sydney
Zhen-Xin Zhang, Beijing
14:30 The New Frontier – Disease Modification for Parkinson's Disease
Nobutaka Hattori, Tokyo
15:00 Advances in the Understanding and Treatment of Channelopathies
Chon-Haw Tsai, Taichung
15:30 New Horizons for Botulinum Injections in Movement Disorders
Raymond Rosales, Quezon City

At the conclusion of this session, participants should be better able to:
1. Describe the landscape of disease modifying therapies in Parkinson's disease
2. Summarize the pathomechanism and emerging treatment of channelopathies
3. Discuss the expanding role of botulinum toxin injection for the treatment of movement disorders

2106 Parallel Session
Hot Topics in Parkinson's Disease Non-Motor Symptoms
16:30 - 18:00
Chairs: Chufeng Liu, Suzhou
Jian Wang, Shanghai
16:30 Treatment of Sleep Disorders in Parkinson's Disease
Jawad Bajwa, Riyadh
17:00 Neuropsychiatric Symptoms in Parkinson's Disease
Jee-Young Lee, Seoul
17:30 Bladder and Sexual Dysfunction in Parkinson's Disease
Priya Jagota, Bangkok

At the conclusion of this session, participants should be better able to:
1. Discuss the presentation and management of sleep disorders in Parkinson's disease
2. Discuss the presentation and management of neuropsychiatric symptoms in Parkinson's disease
3. Discuss the pathophysiology and management of bladder and sexual dysfunction in Parkinson's disease
Saturday, April 13, 2019

2307 Parallel Session
Nondopaminergic System in Parkinson’s Disease
16:30 - 18:00
Chairs: Oscar Gershanik, Buenos Aires
16:30 Norepinephrine and Parkinson’s Disease
Eng-King Tan, Singapore
17:00 Serotonin and Parkinson’s Disease
Pingyi Xu, Guangzhou
17:30 Acetylcholine and Parkinson’s Disease
Chin-Hsien Lin, Taipei
At the conclusion of this session, participants should be better able to:
1. Understand the neuroanatomy and physiology of norepinephrine and clinical implication in Parkinson’s disease
2. Understand the neuroanatomy and physiology of serotonin and clinical implication in Parkinson’s disease
3. Understand the neuroanatomy and physiology of acetylcholine system and clinical implication in Parkinson’s disease

2308 Parallel Session
Chorea in Clinical Practice
16:30 - 18:00
Chairs: Huifang Shang, ChengDu
16:30 The Most Frequent Forms of Genetic and Acquired Chorea in Clinical Practice
Hrishikesh Kumar, Kolkata
17:00 Update on Genetics and Molecular Imaging in Huntington’s Disease
Thomas Kimber, Adelaide
17:30 New Treatment Strategies in Huntington’s Disease and Other Chorea
Hitoshi Okazawa, Tokyo
At the conclusion of this session, participants should be better able to:
1. Recognize the phenomenology of Huntington’s disease and other disorders (Huntington’s disease-like syndromes) in which chorea is the main clinical feature
2. Recognize recent developments in genetics of Huntington’s disease and identify a comprehensive view of molecular imaging biomarkers to study Huntington’s disease
3. Define the latest pharmaceutical and surgical treatment in Huntington’s disease and other chorea

Sunday, April 14, 2019

3101 Plenary Session
MDS-AOS Lectureship Awards
8:00 - 9:30
Chairs: Beomseok Jeon, Seoul
8:00 Philip Thompson Lecture
Shengdi Chen, Shanghai
8:30 Yoshihiko Mizuno Lecture
Ruey-Mei Wu, Taipei

3102 Plenary Session
Comprehensive Management of Parkinson’s Disease
10:00 - 11:30
Chairs: Günther Deuschl, Kiel
10:00 Evidence-Based Management of Parkinson’s Disease
Shen-Yang Lim, Petaling Jaya
10:30 Management of Parkinson’s Disease: A Non-Pharmacological Perspective
Louis Tan, Singapore
11:00 Palliative Care for Parkinsonian Disorders: Why and How?
Vinay Goyal, New Delhi

At the conclusion of this session, participants should be better able to:
1. Explain features that distinguish the different parkinsonian syndromes
2. Categorize hyperkinesia and list appropriate differential diagnoses
3. Recognize characteristics of functional movement disorders

3103 Parallel Session
Gastrointestinal Dysfunction, Weight Loss and Nutritional Aspects in Parkinson’s Disease
14:30 - 16:00
Chairs: Yun Kim, Seoul
14:30 Gastrointestinal Dysfunction in Parkinson’s Disease
Lijuan Wang, Guangzhou
15:00 Gastrointestinal Infections and Microbiome in Parkinson’s Disease
Qin Xiao, Shanghai
15:30 Weight Loss and Nutrition in Parkinson’s Disease, and Management Strategies
Yasuyuki Okuma, Izumokuni
At the conclusion of this session, participants should be better able to:
1. Review aspects of gastrointestinal dysfunction in Parkinson’s disease
2. Discuss the role of gastrointestinal infections and microbiome in Parkinson’s disease
3. Review causes of weight loss and management strategies in Parkinson’s disease

3204 Parallel Session
Clinical Diagnostic Pointers in Making a Diagnosis of a Movement Disorder Condition
14:30 - 16:00
Chairs: Shen-Yang Lim, Petaling Jaya
14:30 Differential Diagnosis of Parkinsonian Disorders
Yiming Liu, Shandong
15:00 Phenomenology of Hyperkinetic Movement Disorders
Thien Thien Lim, Tanjung Bunga
15:30 Diagnosis of Functional Movement Disorders
Oscar Gershanik, Buenos Aires
At the conclusion of this session, participants should be better able to:
1. Review aspects of gastrointestinal dysfunction in Parkinson’s disease
2. Discuss the role of gastrointestinal infections and microbiome in Parkinson’s disease
3. Review causes of weight loss and management strategies in Parkinson’s disease
### Sunday, April 14, 2019

#### Session 3205 Parallel Session

**STN-DBS for Parkinson’s Disease at an Earlier Stage**

**14:30 - 16:00**

**Chairs:** Vincent Mok, Hong Kong  
Chon-Haw Tsai, Taichung

- 14:30 Knowledge, Attitude and Parkinson’s Disease and Their Caregivers  
  Pramod Pal, Bengaluru
- 15:00 Non-Motor Issues in DBS: Neuropsychiatric Effects and Long Term Outcome  
  Young Eun Kim, Anyang
- 15:30 How Early STIM Study Changes Selection Criteria  
  Günther Deuschl, Kiel

At the conclusion of this session, participants should be better able to:
1. Discuss the patient perspective of neuromodulation
2. Describe the neuropsychiatric effects and long term outcome of neuromodulation
3. Discuss the recent data on early STIM study and how it may change patient selection

#### Session 3306 Parallel Session

**Defrosting Parkinson’s Disease: Understanding and Managing Freezing of Gait and Falls**

**16:30 - 18:00**

**Chairs:** Weidong Le, Dalian  
Yasuyuki Okuma, Izunokuni

- 16:30 The Clinical Manifestations and Impacts of Gait Disturbance, Freezing and Falls in Parkinson’s Disease  
  Sue Lord, Auckland
- 17:00 Unlocking the Phenomenology of Freezing with Novel Investigative Techniques  
  Elie Matar, Sydney
- 17:30 Treating Freezing and Falls - Strategies Old and New  
  Vincent Mok, Hong Kong

At the conclusion of this session, participants should be better able to:
1. Recall the clinical associations of freezing of gait and falls in Parkinson’s disease
2. Appreciate the pathophysiology underlying gait disorder in Parkinson’s disease
3. Summarize the current strategies to reduce freezing and falls in Parkinson’s disease

---

### Session 3307 Parallel Session

**Movement Disorders in Vascular Diseases and Hydrocephalus**

**16:30 - 18:00**

**Chairs:** Asha Kishore, Trivandrum  
Qing Wang, Guangzhou

- 16:30 Stroke Induced Movement Disorders – Spectrum and Management  
  Arlene Ng, Quezon City
- 17:00 Small Vessel Disease and Parkinsonism – Evolving Concepts  
  Hirohisa Watanabe, Nagoya
- 17:30 Hydrocephalus and Parkinsonism – Manifestation and Management  
  Rupam Borgohain, Hyderabad

At the conclusion of this session, participants should be better able to:
1. Discuss the spectrum and management of stroke induced movement disorders and strategic lesion locations
2. Discuss the evolving pathogenetic concepts and clinical application of small vessel disease and parkinsonism
3. Identify the optimal balance between medical and surgical management and the clinical complexity of Hydrocephalus and Parkinsonism

---

### Session 3308 Parallel Session

**Biomarkers for Parkinson’s Disease**

**16:30 - 18:00**

**Chairs:** Nobutaka Hattori, Tokyo  
Ruey-Meei Wu, Taipei

- 16:30 New Biomarkers for Parkinson’s Disease  
  Shinji Saiki, Tokyo
- 17:00 Neuroimaging Biomarkers for Parkinson’s Disease  
  Jong-Min Kim, Seongnam
- 17:30 Clinical Biomarkers for Parkinson’s Disease  
  Roongroj Bhidayasiri, Bangkok

At the conclusion of this session, participants should be better able to:
1. Discuss metabolome as a biomarker
2. Discuss neuroimaging as a clinical marker
3. Identify the clinical signs as a phenotypic biomarker

---

For more information or to register, visit [www.aopmc.org](http://www.aopmc.org)